# Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma

> **NCT00626704** · PHASE1,PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 134 (actual)

## Conditions studied

- Locally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma
- Sarcoma
- Soft Tissue Sarcoma

## Interventions

- **DRUG:** AMG 655
- **OTHER:** Placebo
- **DRUG:** Doxorubicin

## Key facts

- **NCT ID:** NCT00626704
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2009-08
- **Final completion:** 2011-03
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2015-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00626704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00626704, "Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00626704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*